Background: Over some 50 years, field surveys have shown that the prevalence of multiple sclerosis (MS) increases with increasing distance from the equator in both the northern and the southern hemispheres. Such a latitudinal gradient has been found in field surveys of MS prevalence carried out at different times in various local regions of Australia. Objective: The objective of this paper is to use a pharmacoepidemiological approach to obtain whole of population estimates of the prevalence of MS in the various Australian states and territories from the use of MS disease-modifying drugs used to treat relapsing-remitting MS (RRMS). Methods: We analysed the dispensed use of subsidised RRMS drugs by jurisdiction. Results: In the 2005-2008 period, the calculated mean treated RRMS prevalence in Australia ranged from 7.5 per 100,000 in the far north to 53.2 per 100,000 in the extreme south and was linearly related to increasing southerly latitude. Public domain Australian data suggested that multiplying this prevalence by a factor of 2.2 (to account for untreated RRMS and other types of MS) may provide a measure of the prevalence of all varieties of the disease. Conclusion: These findings provide contemporary and more comprehensive evidence for the gradient of MS prevalence with latitude in Australia than has previously been available.
Introduction
The prevalence of multiple sclerosis (MS) varies with latitude, and with certain other factors, such as exposure to sunlight in early life 1,2 and regional exposure to ultraviolet radiation. 1 For both the northern and the southern hemispheres, various lines of evidence have demonstrated a tendency for the prevalence of the disease to increase with increasing distance from the equator. The majority of the relevant data have been derived from northern hemisphere populations but findings from the southern hemisphere, including ones from Australia and New Zealand, 3 have shown that MS prevalence increases with increasing southerly latitude. Beginning in 1962 with Sutherland et al. 4 most of the Australian work [5] [6] [7] [8] [9] has comprised field surveys of MS prevalence in selected geographical regions or population centres, though some use has been made of other material such as mortality data. In using such material, there are the inevitable limitations of incomplete case ascertainment and diagnostic uncertainties, as well as the reliability of the regions studied as being representative of the wider population. It therefore seemed worthwhile using a pharmacoepidemiological approach to estimate MS prevalence nationwide, and in the individual states and territories of Australia. Such an approach is made possible by a fortuitous set of circumstances that has applied in relation to the subsidised provision of MS disease-modifying drugs (DMDs) for the whole country.
Methods
In 1996 MS DMDs began to be marketed in Australia, first interferon ß1b, then interferon ß1a in 1999, glatiramer in 2004 and natalizumab in 2008. Fingolimod became available too recently to be considered. The supply of these agents has been heavily subsidised by the Australian Pharmaceutical Benefits Scheme (applicable to the general population) and the Repatriation Pharmaceutical Benefits Scheme (restricted to present and previous Defence Force service personnel and their dependents). The subsidised supply of the MS DMDs has been restricted to persons with relapsing-remitting MS (RRMS) who have experienced at least two attacks or relapses in the previous two years, whose diagnosis was confirmed by magnetic resonance imaging, and in whom the disease did not worsen while receiving the treatment. 10 Thus a clinically isolated syndrome due to MS would be ineligible for subsidised treatment. Primary and secondary progressive MS are excluded by these criteria, as are first-ever attacks of MS and cases with indolent relapsing-remitting disease. After each six months of therapy prescribers are required to re-certify that the criteria for subsidy continue to apply. Supply of only one such drug is subsidised for a given person with MS at any one time. This restriction is possible because individual subsidised prescription records are available to those authorising each prescription (though not to the authors), and because the subsidised provision of such expensive therapy is 'policed'. RRMS in Australia is nearly always managed long term in the community, and without the government subsidy treatment with the drugs would prove prohibitively expensive for nearly all patients. All of the drugs cost in excess of AUD$1000 per month. The maximum co-payment in 2012, if subsidised for general patients, is AUD$35.40 and AUD$5.80 for concession patients. Concessional beneficiaries are those receiving Social Security benefits because they hold a Pensioner card, a Health Care card, or a Commonwealth Seniors Health card. For natalizumab, the monthly unsubsidised cost exceeds AUD$2000 per month. Consequently, virtually all use of RRMS drugs in Australia occurs under the two Pharmaceutical Benefits Schemes and is captured by the Schemes' recording mechanisms. The drug doses employed are almost always a single dosage unit used at the recommended frequency, and the number of dosage units provided by a single prescription with its five repeats is calculated to provide therapy for a total of six months, each 'month' being of 28 days' duration. Therefore, for each calendar year, a person with treated MS will be dispensed 13 'monthly' supplies of the drug used. Hence the number of dispensed subsidised prescriptions of a particular drug each calendar year, divided by 13, will approximate the number of RRMS sufferers taking that drug in that year.
The Australian Government publishes the annual dispensed prescription data, both for the country as a whole and for each Australian state and territory, for drugs subsidised under the Pharmaceutical Benefits Schemes (https://www. medicareaustralia.gov.au/statistics/pbs_item.shtml). These PBS data and official Australian Bureau of Statistics midyear population data 11 have been used in the prevalence calculations in this paper. Natalizumab was considered separately from the other drugs as it is supplied through a special mechanism that may have delayed reports of some of its usage data reaching the Pharmaceutical Benefits Schemes data collection mechanism in the appropriate year. Calculated treated RRMS crude prevalence was expressed per 100,000 of the population for each state or territory, and for the whole country, for each year considered.
As a check on the validity of the above approach, similar prescription data were extracted for two subsidised drugs which have little use except for neurological diseases, viz. riluzole for motor neuron disease and pyridostigmine for myasthenia. No accurate conclusions regarding disease prevalence would be warranted for these drugs, but the prevalences of the diseases for which they are used appear unrelated to latitude. 12, 13 Hence comparing their regional prescription volumes per head of population with those for the MS drugs may reveal unexpected biases in the pharmacoepidemiological approach used to assess MS prevalence.
Results
The dispensed use of individual MS DMDs has increased progressively since their marketing in Australia commenced ( Figure 1 ).
The calculated annual prevalences for treated RRMS in the individual states and territories, and for the whole country, are shown in Table 1 . In the table the states and territories are set out from left to right in order of increasing southerly latitude of their capital cities, around which the great majorities of the populations are congregated. Natalizumab data are shown separately, and not used further in this analysis because of concerns regarding their quality. There is a clear trend for treated RRMS prevalence, estimated from nonnatalizumab data, to increase with increasing southerly latitude. There is an abrupt change in the values for the Australian Capital Territory (ACT) from 2005 onwards which is inconsistent with the data from other administrative regions at relatively similar latitudes. Over the period 2005 to 2008, total dispensed drug use for the whole country appeared to have attained a temporary plateau. After this the introduction Table 1 and on the outline map of Australia in Figure 2 .
Using multivariate linear regression weighted by the standard error of the mean, there was a statistically significant linear relationship between increasing prevalence and increasing south latitude (Figure 3) , the regression equation being: prevalence rate = -13.646 + 1.453 × degree of south latitude; r = 0.957, p = 0.0002. The population of the NT comprises less than 4% 14 of that of the whole country and contains a high proportion (32%) of Indigenous people (in whom MS seems very uncommon, if it occurs at all). If the NT data are excluded, the slope of the regression remains statistically significant (rate = -35.080 + 2.043 × degree of south latitude; r = 0.945, p = 0.0013). Prescriptions per 100,000 people for riluzole and pyridostigmine by administrative region are shown in Table 2 . Except for low values for prescription rates in the NT, the values are reasonably uniform irrespective of latitude of capital city. This behaviour is quite different from that of the MS drug data, suggesting that the calculated values for treated RRMS prevalence based on the pharmacoepidemiological approach are not artefacts of methodology.
Discussion
The calculated treated RRMS prevalence values probably represent reasonable estimates of the true prevalence of this condition across major Australian administrative regions in the 2005-2008 period. Some published Australia data (from TAS 15 ) show that those who take such therapy sometimes miss doses for various reasons, so that their individual prescriptions may last longer than a 28-day period. Any underestimation of prevalence that results from this factor is probably slight, and likely to be non-differential by state and territory. Within their recognised limitations, and restricted applicability to treated RRMS, the data are comprehensive and contemporaneous, unlike the data provided by earlier field surveys of selected regional segments of the population often studied at different times. The approach used here was made possible by several factors: the Australian Government system of subsidising the cost of clinically important medicines for specifically designated indications; mechanisms that ensure that these MS DMDs are used only for the indications specified; the dosage of each of the drugs being virtually identical in all patients; co-administration of other RRMS drugs not being subsidised; and cost almost precluding unsubsidised use of the drugs.
The study provides reasonable evidence of latituderelated differences in the prevalence of treated RRMS in Australia, but incomplete evidence of the situation in relation to MS overall. People with RRMS were not included if they were untreated, by choice, because of previous adverse effects of the therapy, or because their disease process was relatively inactive or was too early in its course for its natural history to be known. Instances of primary progressive MS or secondary progressive disease were not included. Hence the overall prevalence of MS is certainly underestimated by the approach used. Jokubaitis et al. 16 have estimated the proportion of Australians with MS who are currently untreated by DMDs. Of 1618 people with MS identified from MS clinics, 1113 had RRMS. Of these 65% received disease-modifying therapy. 16 Thus 44.7% of the total MS population received these drugs. Since medical, and in particular neurological, standards of practice are believed to be reasonably similar throughout Australia, and these data appear to have been derived from centres in Victoria (VIC), New South Wales (NSW) and Queensland (QLD), it seems that multiplying the prevalence figures obtained in the present study by a factor of 2.2 might provide a reasonable contemporary estimate of the real prevalence of MS in Australia. Thus the national prevalence figure would be around 68 per 100,000 and the TAS figure  117 per 100,000. Simpson et al. 8 published MS prevalence data from a survey carried out in 2009 of the greater Hobart area of TAS, which contains about half of the Tasmanian population. Their crude prevalence figure for the disease was 125.2 per 100,000, consistent with our estimate of 117 per 100,000 from the 2005-2008 data based on the above assumption. The nationwide regional correlation of the calculated prevalence of treated RRMS with southerly latitude found in the present study accords with the findings of earlier Australian field surveys involving limited numbers of geographical sections of the Australian population, carried out at intervals over half a century. The present data have the advantage of comprehensiveness and being more or less simultaneous but the disadvantage of being restricted to one type of MS, albeit the most common type. Nevertheless, the fact that the different methodologies have led to similar conclusions reinforces the finding of the latitudinal gradient in MS prevalence in Australia. In the last analysis, both approaches to determining prevalence depend on recognising the disease. Our approach cannot take the analysis of MS prevalence further, e.g. assessing the effects of factors such as age, place of birth and racial origin, as this information is not available in the public domain in a form which would permit linkage to the drug use data. Nevertheless, it is of interest that a propitious set of circumstances over the time period studied, before oral MS DMDs became available, permitted national dispensed drug use data to be employed to investigate Australian regional prevalence of the disease.
